Brainomix raises €5.5M Bridge round

24 February 2026· Oxford, United Kingdom· health, medical_imaging, ai, b2b, b2g, pure_software

The funding extension will accelerate the company's US rollout of its AI-powered imaging platforms for stroke and lung fibrosis and enhance customer support

Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time, underscoring the need for hospital technologies that support clinicians at the point of care. With this investment extension, we are well-positioned to enhance customer support across the US and Europe, accelerating the seamless integration of our technology into existing clinical workflows and expanding access to life-saving treatments.

Dr Michalis Papadakis, co-founder and chief executive

Investors

LeadParkwalk Advisors
Also participating
Modi VenturesHostplus

About Brainomix

Headquarters
Oxford, United Kingdom
Founded
2010
Team Size
51–200
Sectors
healthmedical_imagingaib2bb2gpure_software

Source: https://www.european-biotechnology.com/up-to-date/news-and-stories/news/brainomix-extends-series-c-to-188m-as-oxford-ai-imaging-spinout-pushes-into-the-us.html